JZP458 in ALL/LBL: Complete follow-up results from AALL1931 trial

^{The phase II/III ALL1931 trial (NCT04145531) assessed the efficacy and safety of JZP458, a recombinant Erwinia asparaginase, in children and adult patients with ALL or LBL who had developed sensitivity to Escherichia coli-derived asparaginases. The complete follow-up results from the trial were published in Blood Advances by Maese. The study evaluated the efficacy and safety of different doses of JZP458 administered MWF in 2 cohorts (IM and IV). The primary efficacy endpoint was safety and the proportion of patients achieving NSAA level of ≥0.1 IU/mL in the last 72 hours during Course 1 of IM JZP458.1}